Published in Cancer Chemother Pharmacol on January 01, 1983
Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst (1998) 3.67
Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med (1987) 3.04
[Effects and costs of adjuvant chemotherapy for operable lymph node positive breast cancer with HER2/neu overexpression]. Ned Tijdschr Geneeskd (2006) 2.65
Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci U S A (1994) 2.52
Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol (2005) 2.39
Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol (1997) 2.29
Clozapine-induced agranulocytosis: a case report. Immunopathophysiological considerations. Neth J Med (1998) 1.98
Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol (2001) 1.92
Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol (2000) 1.89
Chromosomal damage in peripheral blood lymphocytes of patients treated for testicular cancer. Hum Genet (1990) 1.84
Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res (1993) 1.81
Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res (1987) 1.81
Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up. Ann Oncol (2002) 1.80
Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin. Ann Oncol (2002) 1.78
Objectives for an internship internal medicine: from the Dutch Blueprint (Raamplan 1994) to implementation into a practical logbook. Neth J Med (1999) 1.70
Early development of the metabolic syndrome after chemotherapy for testicular cancer. Ann Oncol (2012) 1.70
The molecular genetics of human lung cancer. Eur Respir J (1989) 1.64
Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. J Natl Cancer Inst (1991) 1.64
Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol (1992) 1.62
Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. J Clin Oncol (1995) 1.60
Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: effect of graft size. Ann Oncol (1994) 1.56
Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst (2000) 1.54
Infection prevention in granulocytopenic patients by selective decontamination of the digestive tract. Eur J Cancer (1980) 1.52
Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study. Ann Oncol (2004) 1.52
Endothelium in vitro: a review of human vascular endothelial cell lines for blood vessel-related research. Angiogenesis (2001) 1.52
Value and cost of follow-up after adjuvant treatment of patients with Dukes' C colonic cancer. Br J Surg (2001) 1.51
Malignant struma ovarii treated by ovariectomy, thyroidectomy, and 131I administration. Cancer (1987) 1.50
Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer (2003) 1.50
Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver. Int J Cancer (1991) 1.47
Excessively high cell proliferation in sigmoid colon after an oral purge with anthraquinone glycosides. J Natl Cancer Inst (1995) 1.43
Syndrome X in testicular-cancer survivors. Lancet (2001) 1.43
Combination therapy with cisplatin: modulation of activity and tumour sensitivity. Clin Oncol (R Coll Radiol) (1992) 1.43
At home management of aplastic phase following high-dose chemotherapy with stem-cell rescue for hematological and non-hematological malignancies. Ann Oncol (1999) 1.41
5-Fluorouracil/leucovorin/interferon alpha-2a in patients with advanced colorectal cancer. Effects of maintenance therapy on remission duration. Cancer (1995) 1.40
The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Ann Surg Oncol (2010) 1.38
[Favorable effect of hematopoietic stem cells isolated from blood on hematologic recovery following high-dosage chemotherapy]. Ned Tijdschr Geneeskd (1993) 1.38
Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol (2002) 1.37
Bacteriological aspects of selective decontamination of the digestive tract as a method of infection prevention in granulocytopenic patients. Antimicrob Agents Chemother (1981) 1.37
An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann Oncol (2010) 1.35
Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH). Intensive Care Med (1997) 1.35
Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Ann Oncol (1998) 1.35
Acute and cumulative effects of carboplatin on renal function. Br J Cancer (1989) 1.33
Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res (1990) 1.33
Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation. Br J Cancer (2001) 1.28
Genetic predisposition to testicular germ-cell tumours. Lancet Oncol (2004) 1.28
Prevalence of paraneoplastic hyperthyroidism in patients with metastatic non-seminomatous germ-cell tumors. Ann Oncol (2009) 1.25
Modulation of cis-diamminedichloroplatinum(II) resistance: a review. Br J Cancer (1992) 1.25
Patient motivation and informed consent in a phase I study of an anticancer agent. Eur J Cancer Clin Oncol (1984) 1.23
Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. Hum Gene Ther (2006) 1.22
Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro. Cancer Res (1988) 1.21
Surface roughness, porosity and wettability of gentamicin-loaded bone cements and their antibiotic release. Biomaterials (2000) 1.20
Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients. Blood (1995) 1.19
Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients. Br J Cancer (2003) 1.19
Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers. Br J Cancer (2013) 1.17
Familial testicular cancer in a single-centre population. Eur J Cancer (1999) 1.17
Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. Blood (1994) 1.16
High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy. Br J Cancer (2006) 1.16
Influence of docosahexaenoic acid on cisplatin resistance in a human small cell lung carcinoma cell line. J Natl Cancer Inst (1989) 1.16
Phase II study of bleomycin, dacarbazine (DTIC) and vindesine in disseminated malignant melanoma. J Cancer Res Clin Oncol (1989) 1.16
Comparison of immunocytochemistry, reverse transcriptase polymerase chain reaction, and nucleic acid sequence-based amplification for the detection of circulating breast cancer cells. Breast Cancer Res Treat (1999) 1.16
Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy. Ann Oncol (2010) 1.15
Vincristine pharmacokinetics after repetitive dosing in children. Cancer Chemother Pharmacol (1999) 1.14
Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res (1992) 1.14
The distribution of drug-efflux pumps, P-gp, BCRP, MRP1 and MRP2, in the normal blood-testis barrier and in primary testicular tumours. Eur J Cancer (2004) 1.14
C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J Clin Invest (1994) 1.13
Sexual functioning after treatment for testicular cancer--review and meta-analysis of 36 empirical studies between 1975-2000. Arch Sex Behav (2001) 1.13
Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics. Breast Cancer Res Treat (2011) 1.12
Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy. Br J Cancer (2006) 1.12
Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4. Br J Cancer (1996) 1.12
Some effects of combination chemotherapy with cis-platinum on renal function in patients with nonseminomatous testicular carcinoma. Cancer (1983) 1.09
Characterization of three small cell lung cancer cell lines established from one patient during longitudinal follow-up. Cancer Res (1988) 1.08
Validity and reliability of self-reported exposure to environmental tobacco smoke in work offices. J Occup Environ Med (1997) 1.08
Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. J Pediatr (1994) 1.07
Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol (1993) 1.07
Absence of oncogene amplifications and occasional activation of N-ras in lymphoblastic leukemia of childhood. Blood (1986) 1.06
The detection of minimal numbers of contaminating epithelial tumor cells in blood or bone marrow: use, limitations and future of RNA-based methods. Ann Oncol (1998) 1.06
Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging (2012) 1.05
Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response. Breast Cancer Res Treat (2013) 1.05
The significance of the doctor-patient relationship in coping with cancer. Soc Sci Med (1984) 1.05